| Literature DB >> 31025510 |
Sarah Gniesmer1,2, Ralph Brehm3, Andrea Hoffmann2,4, Dominik de Cassan5, Henning Menzel5, Anna-Lena Hoheisel2,6, Birgit Glasmacher2,6, Elmar Willbold2,7, Janin Reifenrath2,7, Mathias Wellmann7, Nils Ludwig8, Frank Tavassol1, Ruediger Zimmerer1, Nils-Claudius Gellrich1, Andreas Kampmann1,2.
Abstract
In orthopaedic medicine, connective tissues are often affected by traumatic or degenerative injuries, and surgical intervention is required. Rotator cuff tears are a common cause of shoulder pain and disability among adults. The development of graft materials for bridging the gap between tendon and bone after chronic rotator cuff tears is essentially required. The limiting factor for the clinical success of a tissue engineering construct is a fast and complete vascularization of the construct. Otherwise, immigrating cells are not able to survive for a longer period of time, resulting in the failure of the graft material. The femur chamber allows the observation of microhaemodynamic parameters inside implants located in close vicinity to the femur in repeated measurements in vivo. We compared a porous polymer patch (a commercially available porous polyurethane-based scaffold from Biomerix™) with electrospun polycaprolactone (PCL) fibre mats and chitosan (CS)-graft-PCL modified electrospun PCL (CS-g-PCL) fibre mats in vivo. By means of intravital fluorescence microscopy, microhaemodynamic parameters were analysed repetitively over 20 days at intervals of 3 to 4 days. CS-g-PCL modified fibre mats showed a significantly increased vascularization at Day 10 compared with Day 6 and at Day 14 compared with the porous polymer patch and the unmodified PCL fibre mats at the same day. These results could be verified by histology. In conclusion, a clear improvement in terms of vascularization and biocompatibility is achieved by graft-copolymer modification compared with the unmodified material.Entities:
Keywords: PCL fibre mats; angiogenesis; biocompatibility; electrospinning; intravital microscopy; microhaemodynamics
Mesh:
Substances:
Year: 2019 PMID: 31025510 PMCID: PMC6771623 DOI: 10.1002/term.2868
Source DB: PubMed Journal: J Tissue Eng Regen Med ISSN: 1932-6254 Impact factor: 3.963
Figure 1(a–c) Femur chamber. (a) The observation window (Ø10 mm) was fixed by two osteosynthesis screws to the bone and covered with a coverslip, which was secured by a circlip. The observation window was protected with a chamber lid, fixed with two cylinder screws to the chamber frame. (b) In vivo situation with an implant, which was fixed by suture material on the femur (chamber lid removed), 17 days after implantation. (c) In vivo situation with attached chamber lid 17 days after implantation [Colour figure can be viewed at wileyonlinelibrary.com]
Fibre diameter in μm, porosity in %, maximum pore diameter in μm, middle pore diameter in μm, and smallest pore diameter in μm of the control group scaffold (control), the unmodified PCL fibre mat group (PCL), and PCL fibre mat modified with a special fibre modification utilizing chitosan group (CS‐g‐PCL)
| Control | PCL | CS‐g‐PCL | |
|---|---|---|---|
| Fibre diameter (μm) | — | 2.218 ± 0.516 | 2.421 ± 0.501 |
| Porosity (%) | 94.7 | 80.61 | 76.21 |
| Maximum pore diameter (μm) | 175.34 | 9.19 | 8.16 |
| Middle pore diameter (μm) | 139.43 | 6.97 | 6.52 |
| Smallest pore diameter (μm) | 78.14 | 3.81 | 4.71 |
Abbreviation: PCL, polycaprolactone.
Figure 2Scanning electron microscope micrographs of (a) the porous polymer patch (control group), (b) the unmodified polycaprolactone fibre mat, and (c) the CS‐g‐PCL fibre mat
Venular diameters in μm, volumetric blood flow in pl/s, and wall shear rate in s−1 of postcapillary and collecting venules at the border zones of the porous polymer patch control group (control), the unmodified PCL fibre mat group (PCL), and the chitosan‐modified PCL fibre mat group (CS‐g‐PCL) 6, 10, 14, 17, and 20 days after implantation
| Day 6 | Day 10 | Day 14 | Day 17 | Day 20 | |
|---|---|---|---|---|---|
| Diameter (μm) | |||||
| Control | 14.5 ± 0.0 | 18.2 ± 1.1 | 16.8 ± 1.4 | 15.9 ± 1.0 | 15.6 ± 1.4 |
| PCL | 17.0 ± 1.5 | 16.4 ± 0.9 | 17.2 ± 1.4 | 18.0 ± 1.2 | 16.6 ± 1.5 |
| CS‐g‐PCL | 14.0 ± 0.0 | 15.7 ± 1.5 | 18.9 ± 0.8 | 7.4 ± 7.3 | 15.0 ± 1.5 |
| Shear rate (s−1) | |||||
| Control | 159.5 ± 0.0 | 236.0 ± 9.0 | 294.8 ± 30.0 | 245.8 ± 38.0 | 239.0 ± 62.4 |
| PCL | 137.6 ± 33.9 | 228.0 ± 49.6 | 141.3 ± 26.6 | 144.8 ± 28.7 | 120.0 ± 19.2 |
| CS‐g‐PCL | 174.6 ± 0.0 | 134.5 ± 39.1 | 181.9 ± 41.1 | 281.1 ± 0.0 | 232.1 ± 9.7 |
| Volumetric blood flow (pl/s) | |||||
| Control | 30.1 ± 0.0 | 88.7 ± 15.1 | 90.6 ± 22.8 | 58.6 ± 7.8 | 53.2 ± 13.7 |
| PCL | 45.9 ± 16.6 | 59.5 ± 12.8 | 56.6 ± 23.7 | 61.7 ± 24.2 | 32.9 ± 5.9 |
| CS‐g‐PCL | 29.3 ± 0.0 | 32.7 ± 10.3 | 79.8 ± 22.1 | 54.7 ± 0.0 | 51.2 ± 13.2 |
Note. Values are expressed as means ± SEM.
Abbreviation: PCL, polycaprolactone.
Figure 3Neovascularization in the femur chamber model: (a–c) Representative intravital fluorescence microscopy overview images of (a) control, (b) polycaprolactone, and (c) CS‐g‐PCL 20 days after implantation. The centres of the implants are marked (#). (d–f) Quantification of neovascularization expressed as functional capillary density in cm/cm2 (d) in the border zones of the implants, (e) in the centre of the implants, and (f) total functional capillary density expressed as the sum of peripheral and central functional capillary density. All values in this figure represent the mean ± SEM
Figure 4Leukocyte–endothelium interaction at the periphery of the implants in postcapillary and collecting venules after implantation. (a) Number of rolling leukocytes 6, 10, 14, 17, and 20 days after implantation shown as number of cells/min. (b) Number of adherent leukocytes 6, 10, 14, 17, and 20 days after implantation shown as number of cells/mm2. All values in this figure represent the mean ± SEM
Figure 5HE staining, van Gieson staining, and immunohistochemical detection of CD 34: Representative histological stainings (a–o) 20 days after implantation into the femur chamber in Lewis rats. (a–c) HE staining of (1) granulation tissue, (2) implant, and (3) bone. (d–f) HE staining with higher magnification. (g–i) Collagen fibres were detected by van Gieson staining. (j–l) The presence of endothelial cells and accordingly the presence of vascular structures were confirmed by immunohistochemical detection of CD34. (m–o) Negative controls. Areas of the implant are marked (#), and arrows denote vascular structures [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 6Chloracetate‐esterase staining for detection of neutrophilic granulocytes: Representative histological stainings 20 days after implantation into the femur chamber in rats (#) implant [Colour figure can be viewed at wileyonlinelibrary.com]